2022
Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials
Sprangers B, Perazella MA, Lichtman SM, Rosner MH, Jhaveri KD. Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials. Kidney International Reports 2022, 7: 1939-1950. PMID: 36090489, PMCID: PMC9458993, DOI: 10.1016/j.ekir.2022.06.005.Peer-Reviewed Original ResearchChronic kidney diseaseEnd-stage kidney diseaseSevere kidney dysfunctionKidney diseaseKidney dysfunctionAdvanced kidney diseaseOptimal clinical careCancer drug trialsNumber of patientsNarrow therapeutic indexInitial clinical studiesKidney replacement treatmentPreregistration studiesKidney functionCancer careReplacement treatmentCancer trialsClinical trialsEffective dosingClinical studiesTreatment decisionsDrug trialsBeneficial drugsClinical carePatients
2021
PARP inhibitors and the Kidney
Deshpande P, Perazella M, Jhaveri K. PARP inhibitors and the Kidney. Journal Of Onco-Nephrology 2021, 5: 42-47. DOI: 10.1177/2399369320987090.Peer-Reviewed Original ResearchAcute kidney injuryChronic kidney diseaseIschemic acute kidney injuryEnd-stage kidney diseaseKidney diseaseSepsis-related acute kidney injuryAdvanced chronic kidney diseasePARP inhibitorsPoly (ADP-ribose) polymeraseIncrease serum creatinineUse of PARPisBreast cancer gene mutationsStage kidney diseaseAnti-cancer effectsCancer gene mutationsSafe dosingKidney injurySerum creatinineKidney functionKidney effectsClinical trialsLong-term effectsAnimal modelsCellular necrosisPARPis
2020
Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference
Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, Inker LA, Levin A, Mehrotra R, Palevsky PM, Perazella MA, Tong A, Allison SJ, Bockenhauer D, Briggs JP, Bromberg JS, Davenport A, Feldman HI, Fouque D, Gansevoort RT, Gill JS, Greene EL, Hemmelgarn BR, Kretzler M, Lambie M, Lane PH, Laycock J, Leventhal SE, Mittelman M, Morrissey P, Ostermann M, Rees L, Ronco P, Schaefer F, St Clair Russell J, Vinck C, Walsh SB, Weiner DE, Cheung M, Jadoul M, Winkelmayer WC. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney International 2020, 97: 1117-1129. PMID: 32409237, DOI: 10.1016/j.kint.2020.02.010.Peer-Reviewed Original ResearchConceptsAcute kidney injuryChronic kidney diseaseGlomerular filtration rateKidney diseaseKidney functionKDIGO definitionConsensus conferenceSeverity of CKDEnd-stage kidney diseaseAcute kidney diseaseAbsence of symptomsGlobal Outcomes (KDIGO) Consensus ConferenceKDIGO guidelinesKidney injuryKidney failureKidney measuresFiltration rateWorldwide burdenGlobal outcomeKidney structureDiseaseHealth communitySeverityFollowing recommendationsMore effective communicationSGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?
Baker ML, Perazella MA. SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern? Journal Of Nephrology 2020, 33: 985-994. PMID: 32067179, DOI: 10.1007/s40620-020-00712-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetes mellitusAcute kidney injuryChronic kidney diseaseDiabetes mellitusKidney diseaseKidney injuryAlbuminuric chronic kidney diseaseEnd-stage kidney diseaseInhibitor drugsSGLT2 inhibitor therapySignificant cardiovascular benefitsHeart failure hospitalizationGlomerular filtration rateAtherosclerotic cardiovascular diseaseLarge clinical trialsFDA adverse eventsBeneficial cardiovascularKidney benefitsSGLT2 transporterCardiovascular deathFailure hospitalizationAdverse eventsCardiovascular benefitsKidney protectionBlood pressure